Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL27AP5, or ribosomal protein L27a pseudogene 5, is classified as a processed pseudogene derived from the parental RPL27A (ribosomal protein L27a) gene. Pseudogenes have traditionally been viewed as non-functional, but recent studies show that some, such as RPL27AP5, may be transcribed and translated. Specifically, RPL27AP5 expresses two protein variants potentially involved in ribosome biology: a ubiquitin variant (UbP5) and a ribosomal protein variant (S27aP5). These variants mature and localize similarly to their canonical counterparts; S27aP5 can integrate into ribosomes, possibly influencing ribosome complex composition and mRNA association. However, RPL27AP5 is not recognized as a therapeutic target, receptor, enzyme, or transporter in any drug or disease pathway, and its functional relevance is speculative and not established in disease or therapy. It remains primarily a molecular and functional curiosity rather than a canonical pharmacological target.
none; not a current pharmacologic target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L27a pseudogene 5 (RPL27AP5).